81
Participants
Start Date
December 31, 2003
Primary Completion Date
January 31, 2009
Study Completion Date
August 31, 2011
Herceptin
One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
Navelbine
Weekly injections given starting week 3 and ending week 14
Taxotere
Given every three weeks starting week 3 and ending on week 14
Carboplatin
Given every three weeks starting week 3 and ending on week 14
Yale Cancer Center, New Haven
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute
OTHER
Brigham and Women's Hospital
OTHER
Massachusetts General Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Yale University
OTHER
Eric Winer, MD
OTHER